Immunosuppressive therapy is more effective than interferon in neuromyelitis optica

被引：146

作者：

Papeix, C.

Vidal, J-S

de Seze, J.

Pierrot-Deseilligny, C.

Tourbah, A.

Stankoff, B.

Lebrun, C.

Moreau, T.

Vermersch, P.

Fontaine, B.

Lyon-Coen, O.

Gout, O.

机构：

[1] Hop La Pitie Salpetriere, Serv Neurol 1, F-75651 Paris 13, France

[2] Hop La Pitie Salpetriere, Dept Neurol, F-75651 Paris, France

[3] Hosp Salpetriere, INSERM, U708, Paris, France

[4] CHU Lille, Dept Neurol, Lille, France

[5] CHNO, Dept Internal Med, Paris, France

[6] Hop La Pitie Salpetriere, Ctr Invest Clin, Paris, France

[7] CHU Nice, Dept Neurol, Nice, France

[8] CHU Dijon, Dept Neurol, Dijon, France

[9] Fdn Adolphe De Rothschild, Dept Neurol, Paris, France

来源：

MULTIPLE SCLEROSIS | 2007年 / 13卷 / 02期

关键词：

beta interferon; immunosuppressive therapy; neuromyelitis optica;

D O I：

10.1177/1352458506070732

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P=0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants.

引用

页码：256 / 259

页数：4

共 12 条

[1] An open label study of the effects of rituximab in neuromyelitis optica
Cree, BAC
Lamb, S
Morgan, K
Chen, A
Waubant, E
Genain, C
[J]. NEUROLOGY, 2005, 64 (07) : 1270 - 1272
[2] Devic E., 1894, Bull Med, V8, P1033
[3] Autoimmune events during interferon beta-1b treatment for multiple sclerosis
Durelli, L
Ferrero, B
Oggero, A
Verdun, E
Bongioanni, MR
Gentile, E
Isoardo, GL
Ricci, A
Rota, E
Bergamasco, B
Durazzo, M
Saracco, G
Biava, MA
Brossa, PC
Giorda, L
Pagni, R
Aimo, G
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 162 (01) : 74 - 83
[4] Jacob A, 2005, NEUROLOGY, V64, pA328
[5] Plasma exchange for severe attacks of CNS demyelination: Predictors of response
Keegan, M
Pineda, AA
McClelland, RL
Darby, CH
Rodriguez, M
Weinshenker, BG
[J]. NEUROLOGY, 2002, 58 (01) : 143 - 146
[6] A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, VA
Wingerchuk, DM
Kryzer, TJ
Pittock, SJ
Lucchinetti, CF
Fujihara, K
Nakashima, I
Weinshenker, BG
[J]. LANCET, 2004, 364 (9451) : 2106 - 2112
[7] IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, VA
Kryzer, TJ
Pittock, SJ
Verkman, AS
Hinson, SR
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) : 473 - 477
[8] A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
Lucchinetti, CF
Mandler, RN
McGavern, D
Bruck, W
Gleich, G
Ransohoff, RM
Trebst, C
Weinshenker, B
Wingerchuk, D
Parisi, JE
Lassmann, H
[J]. BRAIN, 2002, 125 : 1450 - 1461
[9] Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine
Mandler, RN
Ahmed, W
Dencoff, JE
[J]. NEUROLOGY, 1998, 51 (04) : 1219 - 1220
[10] DEVICS-NEUROMYELITIS-OPTICA - A CLINICOPATHOLOGICAL STUDY OF 8 PATIENTS
MANDLER, RN
DAVIS, LE
JEFFERY, DR
KORNFELD, M
[J]. ANNALS OF NEUROLOGY, 1993, 34 (02) : 162 - 168

← 1 2 →